- Home
- HSII vs RAPP Comparison
HSII vs RAPP Comparison
Compare HSII & RAPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HSII
- RAPP
- Stock Information
- Founded
- HSII 1953
- RAPP 2022
- Country
- HSII United States
- RAPP United States
- Employees
- HSII N/A
- RAPP N/A
- Industry
- HSII Diversified Commercial Services
- RAPP
- Sector
- HSII Consumer Discretionary
- RAPP
- Exchange
- HSII Nasdaq
- RAPP Nasdaq
- Market Cap
- HSII 1.0B
- RAPP 1.2B
- IPO Year
- HSII 1999
- RAPP 2024
- Fundamental
- Price
- HSII $58.78
- RAPP $26.56
- Analyst Decision
- HSII Buy
- RAPP Strong Buy
- Analyst Count
- HSII 2
- RAPP 3
- Target Price
- HSII $57.50
- RAPP $35.33
- AVG Volume (30 Days)
- HSII 554.1K
- RAPP 381.3K
- Earning Date
- HSII 11-03-2025
- RAPP 11-07-2025
- Dividend Yield
- HSII 1.02%
- RAPP N/A
- EPS Growth
- HSII N/A
- RAPP N/A
- EPS
- HSII 1.72
- RAPP N/A
- Revenue
- HSII $1,213,437,000.00
- RAPP N/A
- Revenue This Year
- HSII $11.42
- RAPP N/A
- Revenue Next Year
- HSII $1.39
- RAPP N/A
- P/E Ratio
- HSII $34.17
- RAPP N/A
- Revenue Growth
- HSII 12.82
- RAPP N/A
- 52 Week Low
- HSII $36.87
- RAPP $6.43
- 52 Week High
- HSII $58.79
- RAPP $42.27
- Technical
- Relative Strength Index (RSI)
- HSII 77.71
- RAPP 52.50
- Support Level
- HSII $58.31
- RAPP $25.95
- Resistance Level
- HSII $58.31
- RAPP $29.10
- Average True Range (ATR)
- HSII 0.15
- RAPP 1.85
- MACD
- HSII -0.27
- RAPP -0.01
- Stochastic Oscillator
- HSII 94.53
- RAPP 51.91
About HSII Heidrick & Struggles International Inc.
Heidrick & Struggles International Inc is a leadership advisory firm providing executive search and consulting services to businesses and business leaders world wide. The company's operating segments include the executive search business which operates in the Americas; Europe; Asia Pacific and On-Demand Talent and Heidrick Consulting. It generates maximum revenue from the Americas.
About RAPP Rapport Therapeutics Inc. Common Stock
Rapport Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small-molecule medicines for patients suffering from central nervous system disorders. Its foundational science has elucidated the complexities of neuronal receptor biology and enables the company to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor-associated proteins (RAPs), the latter of which play crucial roles in regulating receptor expression and function.